logo

A breakthrough neuropsychiatry company

A breakthrough neuropsychiatry company

Updated October 2024

Market/Symbol

NYSEAMERICAN:CYBN

Price

$10.78-5.44%

Market Cap

$193m

PE Ratio

0

Average Volume

158k

Pricing delayed 2 hours. Nov 10, 2024 4:00 AM

Investment Thesis

Cybin

Cybin is a neuropsychiatry company developing differentiated, next-generation therapeutics to improve clinical outcomes and address key unmet needs for people with mental health conditions. The company's innovative therapies, CYB003 and CYB004, have the potential to deliver fast-acting, long-lasting relief for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), respectively, with just two doses. With FDA Breakthrough Therapy Designation for CYB003, a robust clinical pipeline approaching critical milestones, and a strong financial position, Cybin is well-positioned to disrupt conventional neuropsychiatric treatments.

Follow the Experts

Quickly navigate key insights from industry experts and leverage their knowledge and market intelligence.

"Anxiety disorders affect over 40 million adults in the United States each year.  In the U.S., GAD is the most common anxiety disorder seen in primary care, with a 12-month prevalence of 2.9%"

Biospace

Biopharma Publications

Get Deeper Insights

What the Pro's Are Asking

Here are the questions that professional investors are asking before making an investment decision.

CYB003 is being developed as an adjunctive therapy to SSRIs for the treatment of major depressive disorder. Additionally, adjunctive dosing allows for immediate treatment without the need to wait for 6-8 weeks to titrate off background medications. Traditional mental health treatments have not significantly changed since the 1980s, do not work on 2/3 of patients, and often do not provide a cure for those it does work on. Cybin's approach involves using deuterated psilocin which has shown promise in clinical trials for effectively treating conditions like depression, anxiety, and addiction, potentially offering new and more effective treatment options, without having to force patients to come off their SSRIs.
Get real time
updates
logo
Company News
logo
Expert insight
logo
Market news

External Insights

A curated collection of third-party content relevant to the company and sector to help inform your investment decision.

Team

team member

Doug Drysdale

Chief Executive Officer

Doug, an experienced CEO and Corporate Director has led multiple pharmaceutical companies for the last 30 years, raised $4 billion, completed 15 acquisitions, and significantly increased revenues and enterprise value. He was recognized as Entrepreneur of the Year in 2012
team member

Aaron Bartlone

Chief Operating Officer

Aaron is the Former Chief Quality, Patient Safety, HSE & Risk Officer and President at UCB, Inc., leading global teams and US operations. Held various director roles at Eli Lilly.
team member

Greg Cavers

Chief Financial Officer

Greg Cavers, Chief Financial Officer with 15+ years of experience in financial operations, regulatory reporting, and IFRS, has held senior roles at Ontario Securities Commission, Scotiabank, Global Maxfin Investments, and CIBC.
team member

Eric So

Co-founder, Executive Chairman and President

Co-founder and Managing Director of Trinity Venture Partners Inc., with extensive experience as a founder, investor, and advisor. He began his career in corporate law and has raised hundreds of millions for companies, facilitating exits and liquidity events. He holds a B.Sc. in Anatomy and Cell Biology a Bachelor of Laws

Let's Connect

Complete the form to contact the investor relations team.
Follow our socials
We post updates and content every day on the companies we showcase. Follow to be sure you don't miss anything!
Join our mailing list
To keep up-to-date with the companies showcased
You can also email us at

logoAny questions?

Contact: Nirav Karia -

nirav.karia@curationcorp.com

General disclaimer and copyright

This showcase has been commissioned by the Business and prepared and issued by Curation, in consideration of a fee payable by the business. Fees are paid in cash without recourse. Curation may seek additional fees for the provision of content and related IR services for the client but does not get remunerated for any investment banking services.Accuracy of content: All information used in the publication of this showcase has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this showcase and have not sought for this information to be independently verified. Opinions contained in this showcase represent those of Curation at the time of publication. Forward-looking information or statements in this report may contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.Exclusion of Liability: To the fullest extent allowed by law, Curation shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this showcase.No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Curation's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.Investment in securities mentioned: Curation does not itself hold any positions in the securities mentioned in this report, nor the analysts who responsible for compiling this showcase. However, the respective directors, officers, employees and contractors of Curation may have a position in any or related securities mentioned in this showcase, subject to Curation's policies on personal dealing and conflicts of interest.

United Kingdom

This document is prepared and provided by Curation for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Curation relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This showcase is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Curation does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.